TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00850395

Intervention type: DRUG
Intervention: maraviroc
Description: No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
Study: NCT03676530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro-Tec Shin Splint Compression Wrap
Description: EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
Study: NCT02361255

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT00193882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 IV day 1

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 35 Gy in 15 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 35 Gy in 15 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 800mg/m2/day IV days 1 - 4
Study: NCT03447665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime routine
Description: Tailored bedtime routine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime routine
Description: Tailored bedtime routine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep schedule
Description: Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep schedule
Description: Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (bedtime)
Description: Parents implement behavioral sleep intervention at bedtime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (bedtime)
Description: Parents implement behavioral sleep intervention at bedtime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (after night wakings)
Description: Parents implement behavioral sleep intervention following each night waking.
Study: NCT00477672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 10 mg, tablet, once daily by mouth, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 40 mg, tablet, once daily by mouth, 6 weeks
Study: NCT02783092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
Study: NCT00856544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Film coated tablet, 5 mg PO BID, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Film coated tablet, 10 mg PO BID, 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablet, 1 tablet PO BID, 3-6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablet, 1 tablet PO BID, 3-6 months
Study: NCT00625781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart and Insulin human (isophane)
Description: Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
Study: NCT02435927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
Description: ASLAN001 in combination with oxaliplatin and capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001 + mFolfox6 (5-FU, leucovorin)
Description: ASLAN001 in combination with 5-FU and leucovorin
Study: NCT03963427

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast reconstruction
Description: Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
Study: NCT00477672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily by mouth, 6 weeks
Study: NCT02739269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum AMH measurement
Description: Serum AMH is measured one month before the IVF treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: AFC measurement
Description: Early follicular phase AFC is measured one month before the IVF treatment
Study: NCT01914224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary education of low sodium and high potassium consumption

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary education of low sodium consumption only
Study: NCT03806686

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study: NCT01736696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 5 mg BID For 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 10 mg BID for 13 days and once on Day 14\*

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 20 mg BID for 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 30 mg BID for 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 60 mg tablet once a day (QD) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 50 mg tablets two times a day (BID) for 13 days and once on day 14
Study: NCT02386696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Lung ultrasound examination on healthy volunteers
Study: NCT03289507

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment1
Description: Longvida Capsule formulation A

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment2
Description: Longvida Capsule formulation B

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment3
Description: Curcuma longa extract of Rhizomes
Study: NCT03654482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperSeton
Description: The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
Study: NCT03806686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study: NCT00568126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Description: 3g/day of Maca Root for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study: NCT03122314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
Study: NCT01209442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (Radiation Therapy)
Description: Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
Study: NCT01256112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Supported Behavioral Intervention
Description: Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/Activity Education (NAE)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition/Activity Education (NAE)
Study: NCT00405548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP (nesiritide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03247166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS™ System
Description: The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
Study: NCT01709695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Hydrochloride XR
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Study: NCT03072485

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Topical sirolimus applied to the skin

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Topical metformin applied to the skin

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Topical metformin applied to the skin

Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: Topical diclofenac applied to the skin

Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: Topical diclofenac applied to the skin
Study: NCT00546611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005
Study: NCT00581568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cutaneous Effects of Cryogen Spray Cooling
Description: Cutaneous Effects of Cryogen Spray Cooling
Study: NCT04505566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.45% ophthalmic solution
Description: Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Preservative-free artificial tears
Description: Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.

Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured

Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured

Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
Study: NCT01398046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: dasatinib (100mg) PO x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Rabeprazole
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
Study: NCT02428439

Intervention type: DRUG
Intervention: bupropion or lamotrigine
Description: Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.

Intervention type: DRUG
Intervention: bupropion or lamotrigine
Description: Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
Study: NCT03228797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: an ultrasound guided rectus sheath block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiholed catheter
Description: gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: an ultrasound guided rectus sheath block &multiholed catheter
Description: a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
Study: NCT01822717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonvisual foot inspection
Description: Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
Study: NCT02856555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsules orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to firsocostat orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to firsocostat orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to firsocostat orally once daily.
Study: NCT03424356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.15 mg/kg rocuronium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: 1-2 ml saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 1mcg/kg for induction
Study: NCT02634593

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load snacks
Description: Intervention to replace standard night-time food and drinks with lower glycemic load options
Study: NCT02173457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Take orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Take orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Take orally
Study: NCT01742585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT02699619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinloc
Description: 3 hook pins interlocked in plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Hansson pins
Description: 2 isolated hook pins.(Without plate)
Study: NCT00882856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol Vitabalnas 10 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol Vitabalnas 10 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03424356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1mcg/kg for induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2-3mg/kg for anaesthetic induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-3mg/kg for anaesthetic induction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: patients will treated with this surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cystoscopy
Description: patients will treated with this surgical procedure
Study: NCT01387464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% bromfenac in DuraSite dosed QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromday™
Description: 0.09% bromfenac dosed QD
Study: NCT01858740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
Study: NCT02443558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERCURY v2.0 robotic arms
Description: MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MERCURY v2.0 robotic arms
Description: MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
Study: NCT01858740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
Study: NCT00882856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03780634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
Study: NCT01858740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT03400163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: BMS-986036 20 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study: NCT02241343

Intervention type: DEVICE
Group type: OTHER
Intervention: Venous occlusion (leg tourniquet, made in-house)
Description: Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
Study: NCT02997059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 200 mg/ day
Study: NCT03780634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 200mg intravenously every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg Bid Po
Study: NCT01212809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra
Description: Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
Study: NCT02997059

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00729963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP